Biomx Inc Asset Resilience Ratio
Biomx Inc asset resilience ratio. Biomx Inc (PHGE) has an Asset Resilience Ratio of 1.86% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Biomx Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Biomx Inc (2017–2023)
Asset resilience ratio of Biomx Inc from 2017 to 2023. This chart shows how Biomx Inc's Asset Resilience Ratio has changed over time. Read Biomx Inc (PHGE) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Biomx Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Biomx Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.11 Million | 1.86% |
| Total Liquid Assets | $1.11 Million | 1.86% |
Asset Resilience Insights
- Limited Liquidity: Biomx Inc maintains only 1.86% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Biomx Inc Industry Peers by Asset Resilience Ratio
Compare Biomx Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Biomx Inc Asset Resilience Ratio by Year (2017–2023)
Biomx Inc asset resilience ratio by year from 2017 to 2023. The table below shows the annual Asset Resilience Ratio data for Biomx Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $25.03 Million | -- |
| 2022-12-31 | 4.39% | $2.00 Million | $45.53 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $77.99 Million | -- |
| 2020-12-31 | 28.21% | $19.85 Million | $70.36 Million | +17.35pp |
| 2019-12-31 | 10.86% | $10.00 Million | $92.12 Million | -57.65pp |
| 2018-12-31 | 68.51% | $31.05 Million | $45.33 Million | +60.26pp |
| 2017-12-31 | 8.25% | $1.15 Million | $13.99 Million | -- |
About Biomx Inc
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic f… Read more